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Background: The forced expiratory volume at first second (FEV1) during spirometry reflects the
severity of chronic obstructive pulmonary disease (COPD) and is known to be an important
prognostic factor. It is uncertain whether the response to short-acting bronchodilators may
predict long-term outcomes such as hospitalizations and mortality.
Methods: We retrospectively studied a total of 1203 consecutive COPD patients without signif-
icant comorbidities during a mean (SD) of 69  39 months of follow-up. At baseline the sub-
jects were classified as those with positive or negative bronchodilator test (BDT) and also in
quartiles of absolute bronchodilator response to 400 mg of salbutamol. Hospital visits and mor-
tality were the end points.
Results: A positive bronchodilator test was observed in 332 (27.6%) of the patients. There were
73 (21.9%) deaths in patients with a positive BDT versus 253 (28.7%) in those with a negative
BDT (pZ 0.04). In adjusted Cox regression analysis a positive BDT was significantly associated
with a prolonged time to first hospitalization. After stratifying the population by quartiles of
response to BDT, a doseeresponse relationship was observed with the best outcomes in the
quartile with highest level of airflow reversibility, even after controlling for age, sex, BMI,




Reversibility and prognosis in COPD 1181Conclusions: In a large population of well characterized COPD patients without significant co-
morbidities, those demonstrating higher levels of reversibility at baseline presented better
long-term outcomes even after controlling for other known prognostic factors.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
In Spain, up to 10.2% of the adult population is affected by
chronic obstructive pulmonary disease (COPD) [1]. This
chronic and debilitating disease is associated with an
impairment in quality of life and a reduction of survival [2].
Several prospective studies have attempted to identify
factors associated with poor outcomes such as hospitali-
zations and/or mortality [3e8], including multidimensional
indices [9,10].
Acute bronchial reversibility after inhalation of a short-
acting beta-2 agonist has been traditionally used to
differentiate asthma from COPD. However, it is clear that a
positive reversibility test does not exclude the diagnosis of
COPD [11]. In the ECLIPSE cohort, 24% of patients with
COPD met the criteria for reversibility [12], although
bronchodilator status (positive or negative) varied tempo-
rally and did not differentiate clinically relevant outcomes
[12,13]. Given the arbitrary nature of the established
thresholds, the changes in positive or negative status may
represent small increases or decreases in reversibility that
move individual patients from one side to the other of the
threshold; i.e. from 11.8% to 12.2% increase in FEV1 or
viceversa, which in reality may not represent clinically
meaningful changes in reversibility [14].
To investigate the impact of reversibility on long-term
outcomes, we followed a cohort of well characterized
COPD patients and analyzed the outcomes according to the
result of the bronchodilator test. We also extended the
analysis by dividing the population into quartiles of bron-
chodilator response to investigate a possible dos-
eeresponse effect of reversibility on hospitalizations and
mortality.Method
We retrospectively identified all consecutive newly
referred patients from January 1st, 1996 to November 30th,
2008, for pulmonary function evaluation to the Hospital
Universitario Miguel Servet (Zaragoza, Spain). Eligible pa-
tients were those with diagnosed COPD defined by a history
of current or ex-smokers of at least 20 pack-years and a
post-bronchodilator FEV1/FVC < 0.7. Patients with history
of malignancy at baseline or history of asthma, those with
any comorbidity included in the Charlson index [15] and
those who were unable to perform the required tests were
excluded. We also excluded nonresidents in the region due
to the difficulties in follow-up. The study was approved by
the research review board of the Hospital Universitario
Miguel Servet (Zaragoza, Spain).Measurements
Baseline variables were systematically recorded at the
pulmonary function laboratory using a standardized proto-
col. The ATS-DLD-78 adult questionnaire [16] was adminis-
tered before the PFTs. Dyspnea was assessed using the
modified Medical Research Questionnaire dyspnea scale
[17]. The pulmonary function tests (PFTs) were performed
according to the guidelines of the American Thoracic So-
ciety (ATS) [18] when patients had been in stable condition
for at least 6 weeks. Spirometric reference values were
those of the European Community for Coal and Steel (ECCS)
[19]. Bronchodilator treatment was withdrawn prior to the
PFTs according to standard practice. A qualified pulmonary
technologist conducted maximal in-and expiratory flow
volume curves with subjects seated before and after
administration of 400 mg salbutamol via a metered dose
inhaler with a large volume spacer. The “best curve” was
selected from the largest sum of FEV1 and forced vital ca-
pacity (FVC). Bronchodilator responsiveness (BDR) was
calculated according to ATS guidelines [18]. A FEV1 change
from initial less than 12% and FEV1 absolute change less
than 200 mL was considered as a negative BDR.
Follow-up
Patients attended the pulmonary clinics at least once a year
or until death and the history of exacerbations of COPD and
hospitalizations was obtained at each visit. The end points of
this studywere: 1) first severeCOPDexacerbation, definedas
an exacerbation of COPD requiring an emergency room visit
and or hospitalization, 2) all cause hospitalization, 3) death
by all causes and death due to COPD and 4) first respiratory
event, including emergency room visit or hospitalization for
an exacerbation or respiratory death. The occurrence of
each endpoint was thoroughly assessed by reviewingmedical
records and computerized databases, andwhennecessary by
contacting the primary care physician and/or the pulmo-
nologist in charge of the patient.
Statistical analysis
Categorical variables were compared with the Chi-square
test or Fisher’s exact test when appropriate. Continuous
variables were compared using the Student’s t-test or the
one way analysis of variance (ANOVA) where appropriate.
The rates of emergency visits and hospitalizations were
calculated as the number of episodes divided by the years
of follow-up. All post-hoc comparisons were made with the
Bonferroni correction for multiple comparisons.
1182 J.M. Marı´n et al.The time to each of the end points was compared among
the different groups by means of Cox regression model
adjusted by the following variables: age, sex, BMI, smoking
status and postbronchodilator FEV1 (% predicted). Data
were processed with the SPSS 17.0. The level of significance
was set at 0.05 (two-tailed).
Results
During the period of the study 7894 individuals were
referred for PFTs, of which 3013 (38.1%) were diagnosed
with COPD. Of these, 1203 fulfilled the inclusion criteria
and were included in the study (Figure 1). At baseline the
mean age was 63 years (SD Z 9.1 years), 93.4% were men
and the mean prebronchodilator FEV1 was 57.5% pre-
dicted (SD Z 20.1%). A positive bronchodilator test
(BDTþ) was observed in 332 (27.6%). Patients with a BDTþ
were more frequently men and had significantly reduced
values of all spirometric parameter prebronchodilator.
However, there were no significant differences in all
postbronchodilator spirometric parameters between pa-
tients with positive or negative BDT (Table 1). No differ-
ences were observed in patterns of pharmacologic
treatment either at entry in the cohort or at the end of
follow-up (Table 1).
Hospital visits and mortality according to results of
BDT
The mean follow-up time was 69.1 months, being signifi-
cantly longer for the group with BDT þ (75.2 (SD Z 39.6)Figure 1 Description of the population inclumonths vs. 66.9 (SD Z 39.3); p Z 0.002). The rate of hos-
pitalization for COPD was significantly lower for BDTþ pa-
tients and the time to the first hospitalization was
significantly prolonged (39.3 months (SD Z 31.5) vs. 32.4
months (SD Z 30.2); p Z 0.028) (Table 2). Hospitalization
rates for other causes did not differ between groups, but
the time to the first hospitalization was significantly longer
in PBD þ patients (37 months (SD Z 31.7) vs 30.6 months
(SD Z 29.4); p Z 0.024). The time to the first respiratory
event was also significantly prolonged for BDT þ patients
(29 months (SD Z 27.8) vs. 24.3 months (SD Z 25.6);
p Z 0.009) (Table 2).
All-cause mortality was significantly reduced in
BDT þ patients (21.9% vs. 28.7%; p Z 0.04). However, the
reduction in mortality for COPD in BDTþ patients just failed
to reach statistical significance (10.5% vs. 17%; p Z 0.072)
(Table 2).Time to hospitalization and death according to BDT
The results of the adjusted Cox regression model for time to
the first hospitalization according to BDT results are shown
in Table 3 and Figure 2(a). Together with a BDT-, the only
variables significantly associated with a shorter time to first
hospitalization were the older age group (>65 years), low
BMI and low postbronchodilator FEV1 (%).
A BDT- was associated with a significantly shorter time to
first respiratory event together with age >65, female sex,
low BMI, and lower post-bronchodilator FEV1 (%) (Table 3
and Figure 2(b)).ded in the study and reasons for exclusion.
Table 1 Patient characteristics according to response to the bronchodilator test.





Sex, men (%) 1124 (93.4) 814 (92.4) 310 (96.3) 0.01
Age, years 63 (9.1) 63.1 (9.1) 62.8 (8.9) 0.60
BMI, Kg/m2 27.5 (4.7) 27.3 (4.7) 28 (4.6) 0.01
Current smoker 412 (34.9) 302 (35) 110 (34.7) 0.94
Former smoker 769 (65.1) 562 (65) 207 (65.3)
Packs-year 52.3 (25.3) 52.7 (25.4) 51 (25) 0.21
Pre-bronchodilator spirometry
FVC, mL 3134 (873) 3168 (894) 3.041 (807) <0.001
FVC, % 88.4 (19.7) 89.8 (20.1) 84.7 (18.1) <0.001
FEV1, mL 1610 (657) 1665 (685) 1461 (546) <0.001
FEV1, % 57.5 (20.1) 59.6 (20.8) 51.7 (16.9) <0.001
FEV1/FVC, % 50.6 (11.9) 51.6 (12.1) 47.8 (10.7) <0.001
Post-bronchodilator spirometry
FVC, mL 3339 (869) 3288 (884) 3480 (812) <0.001
FVC, % 94.4 (19) 93.5 (19.6) 96.9 (17.4) 0.02
FEV1, mL 1747 (672) 1733 (692) 1784 (612) 0.16
FEV1, % 62.3 (20.3) 62.2 (21) 62.6 (18.3) 0.86
FEV1/FVC 51.8 (12.1) 52.8 (12.4) 48.9 (10.9) <0.001
Change in FEV1, mL 136 (162) 68 (106) 323 (141) <0.001
Change in FEV1, % 10.1 (12) 5 (7.3) 24.2 (10.9) <0.001
COPD medications at entry (%)
None 35.6 36.3 32.9 0.28
SABA or SAMA only 15.4 15.5 14.7 0.78
LABA 4.8 4.4 5.4 0.44
LAMA 10.2 10.1 10.2 0.91
ICS only 3.1 2.4 4.2 0.12
LABA þ ICS 17.9 17.6 21.4 0.13
LAMA þ ICS 2.6 2.2 3.3 0.30
LABA þ LAMA 3.2 3.4 2.8 0.58
LABA þ LAMA þ ICS 7.2 8.0 5.1 0.08
COPD medications at last follow-up or at time of death (%)
None 19.3 19,9 17,8 0.51
SABA or SAMA only 2.0 2.1 1.9 0.79
LABA 1.4 1.5 1.2 1.00
LAMA 15.4 16.0 13.9 0.47
ICS only 1.8 1.6 2.3 0.58
LABA þ ICS 28.7 28.1 30.1 0.56
LAMA þ ICS 1.8 1.8 1.9 1.00
LABA þ LAMA 6.3 6.5 5.7 0.76
LABA þ LAMA þ ICS 23.3 22.5 25.1 0.43
BMI: Body mass index; SABA: Short-acting beta-2 agonist; SAMA: Short-acting anticholinergic; LABA: Long-acting beta-2 agonist; LAMA:
Long-acting anticholinergic; ICS: Inhaled corticosteroid.
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bronchodilator response in quartiles
The most reversible group (Q4) included significantly more
men and the prebronchodilator FEV1 (%) was lower (Table 4).
Patients in the Q4 had better outcomes during follow-up
compared with the remaining groups (Table 5). The hospi-
talization rate for Q4 was 0.6 event per year (SD Z 1.5)
compared with 1 (SD from 1.9 to 2.8) for the rest of patients
(p Z 0.025). Time to hospitalization for all causes was
significantly prolonged forQ4 (pZ 0.015). All causemortality
was significantly reduced for Q4 (20.5% comparedwith 28.4%,30.4% and 29.2% for Q1, Q2 and Q3, respectively; pZ 0.025),
but mortality by COPD was not significant (pZ 0.093).
Time to hospitalization and death according to
bronchodilator response in quartiles
Patients in Q4 had a significantly prolonged time to the first
hospitalization compared with the remaining quartiles,
after adjusting for the remaining variables. Older age, low
BMI and a lower postbronchodilator FEV1 (%) were also
significantly associated with reduced time to the first hos-
pitalization (Table 6 and Figure 3(a)).
Table 2 Follow-up of patients according to bronchodilator response.





Mean follow-up time, months (SD) 69 (39) 67 (39) 75 (40) 0.002
Hospitalization for COPD (%) 395 (33) 304 (34.7) 91 (28.4) 0.04
Hospitalization ratea 0.9 (2.1) 1 (2.3) 0.7 (1.6) 0.02
Time to first hospitalization, months (SD) 34 (30.7) 32.4 (30.2) 39.3 (31.5) 0.02
Hospitalization for other causes (%) 562 (46.9) 412 (46.9) 150 (46.7) 1
Hospitalization ratea 1.1 (2) 1.2 (2.1) 1.1 (1.7) 0.73
Time to hospitalization, months (SD) 32.4 (30.2) 30.6 (29.4) 37 (31.7) 0.02
Emergency visits for COPD (%) 863 (72.3) 641 (73.3) 222 (69.4) 0.18
Visits ratea 3.6 (5.5) 3.7 (5.6) 3.4 (5.2) 0.12
Time to first access, months (SD) 24.3 (24.5) 23.6 (24.3) 26.2 (24.7) 0.09
Mortality for COPD (%) 184 (15.3) 150 (17) 34 (10.5) 0.07
Time to death, months (SD) 52.5 (33.9) 51.3 (34.7) 57.6 (29.5) 0.21
All-cause mortality (%) 326 (27.1) 253 (28.7) 73 (21.9) 0.04
Time to death, months (SD) 54.1 (33.6) 53.3 (34.1) 57 (32) 0.35
Time to first respiratory event, months (SD) 25.5 (26.3) 24.3 (25.6) 29 (27.8) 0.009
a Rates are expressed as mean number of events per patient during follow-up.
1184 J.M. Marı´n et al.Similarly, patients in Q4 had a prolonged time to the first
respiratory event after adjustment (Table 6 and
Figure 3(b)). Older age, low BMI and lower post-
bronchodilator FEV1 (%) were also significantly associated
with reduced time to the first respiratory event. In this caseTable 3 Results of adjusted Cox regression analysis for
shorter time to the first hospitalization and shorter time to




Time to first hospitalization
BDTþ 0.734 0.578e0.933 0.012
Age, older than 65 yrs 1.777 1.437e2.197 <0.001
Sex, men 0.819 0.512e1.311 0.405
BMI, Kg/m2
Normal (18.5e25) 1 e e
High (25e30) 0.899 0.704e1.148 0.395
Very high (>30) 0.990 0.752e1.304 0.945
Low (<18.5) 3.210 1.929e5.342 <0.001




Time to first respiratory event
BDTþ 0.820 0.706e0.952 0.009
Age, older than 65 yrs 1.438 1.255e1.647 <0.001
Sex, men 0.748 0.568e0.986 0.039
BMI, Kg/m2
Normal (18.5e25) 1 e e
High (25e30) 0.998 0.848e1.174 0.976
Very high (>30) 1.108 0.925e1.327 0.267
Low (<18.5) 2.208 1.427e3.416 <0.001




BDT: Bronchodilator test; BMI: Body mass index.female gender was also significantly associated with a
shorter time to the event (Table 6).Discussion
The results of the current study show that patients with a
positive BDT have a better prognosis demonstrated by a
significantly reduced hospitalization rate for COPD and a
reduced all-cause mortality, with an almost statistically
significant reduction in mortality for COPD. These patients
also had a significantly prolonged time to the first respira-
tory event (either death, hospitalization or emergency
room visit for an exacerbation). These differences persisted
after adjusting by age, postbronchodilator FEV1 and smok-
ing habits. Furthermore, by dividing the population into
quartiles of bronchodilator response, we verified that there
is a doseeresponse relationship in most long-term out-
comes evaluated, being better in patients with a more
reversible BDT. Our series is unique because the selection
criteria allowed analysis of the influence of reversibility on
outcomes without the confounding factor of severe
comorbidities.
It has been repeatedly demonstrated that bronchodi-
lator reversibility status varies temporally and, therefore,
classifying COPD patients into positive or negative BDT does
not have prognostic implications and does not help in
therapeutic decisions [12,13]. The problem stems in the
dichotomization of a continuous variable; the reversibility
of most COPD patients is close to the threshold of what is
considered a positive (reversible) BDT [13,20]. Therefore,
small random changes in reversibility (or just the normal
variability of the measurement) may lead a subject to
switch sides of the arbitrary threshold. These changes in
reversibility status (from positive to negative or viceversa)
may not relate to differences in clinical, physiological or
phenotypic characteristics. To really address the issue of
the importance of variability in reversibility, it is better to
determine the magnitude of the difference in
Figure 2 (a) Probability of hospitalization for COPD during follow-up in patients with positive or negative BDT. Adjusted Cox
regression model. (b) Probability of first respiratory event during follow-up in patients with positive or negative BDT. Adjusted Cox
regression model.
Reversibility and prognosis in COPD 1185bronchodilator response between measurements for each
individual over time rather than the changes defined as
positive or negative status, and relates the magnitude of
change to differences in clinical outcomes of importance.
This is highlighted by the results of the Lung Health Study
which demonstrated that after the first year of follow-up
there was no change in absolute bronchodilator response
in mild COPD patients who were sustained quitters [21],
supporting the idea of some stability in bronchodilator
response, at least when the influence of changes in smoking
status is avoided.
In further supporting the view of bronchodilator
response as a continuous measurement, our results suggestTable 4 Characteristics of patients according to bronchodilato
Q1 < 40 mL
(n Z 299)
Q2  40 and <120 mL
(n Z 289)
Sex, men (%) 217 (90.6) 264 (91.3)
Age, years 62.6 (9.8) 63.2 (8.4)
BMI, Kg/m2 27.2 (4.9) 27.2 (4.7)
Current smoker 123 (42) 104 (36.7)
Former smoker 170 (58) 179 (63.3)
Packs-year 53.5 (25.7) 53 (23.1)
Pre-BD spirometry
FVC, mL 3213 (922) 3052 (864)
FVC, % 91.4 (19.8) 87.7 (20.2)
FEV1, mL 1732 (716) 1560 (645)
FEV1, % 61.9 (21.4) 56.8 (20.5)
FEV1/FVC, % 52.8 (12.5) 50.5 (12.3)
Post-BD spirometry
FVC, mL 3201 (903) 3185 (837)
FVC, % 91.2 (19.6) 91.9 (19.7)
FEV1, mL 1691 (710) 1638 (646)
FEV1, % 60.6 (21.1) 59.7 (20.6)
FEV1/FVC 54 (12.8) 51.1 (12.6)
Change in FEV1, mL 41 (93) 78 (24)
Change in FEV1, % 2.3 (5.7) 6 (3.2)
BDT: Bronchodilator test; BMI: Body mass index.that there is a continuum in the long-term outcomes ac-
cording to the intensity of the response, with the best
outcomes observed in patients with the highest revers-
ibility. Interestingly, the magnitude of reversibility was far
from the currently accepted threshold of 200 mL and 12%
increase in FEV1. In fact, patients in the highest quartile of
reversibility, who showed the best outcomes, had a mean
FEV1 reversibility of 333 mL or 23.7%.
It could be argued that the better outcomes in this more
reversible quartile could be due to the inclusion of asth-
matics. However, we excluded all patients with a previous
diagnosis of asthma and the demographic and clinical
characteristics of patients in this quartile were similar tor response in quartiles.
Q3  120 and <220 mL
(n Z 312)
Q4  220 mL
(n Z 303)
p Value
295 (94.6) 294 (97) 0.005
64.2 (8.8) 62.1 (9.1) 0.02
27.5 (4.7) 28.1 (4.5) 0.13
80 (26.1) 105 (35.2) 0.001
227 (73.9) 193 (64.8)
52.5 (28) 50 (24) 0.32
3084 (840) 3185 (859) 0.06
87.3 (19.5) 87.3 (19.2) 0.02
1564 (634) 1586 (618) 0.003
56.4 (19.3) 55 (18.8) <0.001
50 (11.5) 49.2 (10.9) 0.001
3335 (821) 3626 (845) <0.001
94.9 (17.8) 99.4 (18) <0.001
1733 (635) 1919 (663) <0.001
62.7 (19.4) 66.1 (19.5) 0.001
51.2 (11.8) 50.3 (11.1) 0.002
169 (30) 333 (141) <0.001
12.6 (5.4) 23.7 (11.6) <0.001
Table 5 Follow-up of patients according to quartiles of bronchodilator response.
Q1 < 40 mL
(n Z 299)
Q2  40 and
<120 mL
(n Z 289)
Q3  120 and
<220 mL
(n Z 312)
Q4  220 mL
(n Z 303)
p Value
Mean follow-up time, months (SD) 63.7 (37) 66.6 (40.3) 70.4 (40.4) 75.3 (39) 0.002
Hospitalization for COPD (%) 100 (33.9) 118 (41) 103 (33) 74 (24.6) 0.001
Hospitalization ratea 1 (2.2) 1 (1.9) 1 (2.8) 0.6 (1.5) 0.02
Time to first hospitalization, months (SD) 31 (29.1) 32.7 (31.7) 33.8 (30.7) 40 (30.5) 0.26
Hospitalization for other causes (%) 136 (45.8) 130 (45.1) 159 (51) 137 (45.4) 0.41
Hospitalization ratea 1.2 (2.2) 1.2 (2.4) 1.2 (1.7) 1.1 (1.7) 0.82
Time to hospitalization, months (SD) 25.4 (27.3) 32.2 (30.2) 35.2 (31.2) 36.1 (30.9) 0.01
Emergency visits for COPD (%) 210 (70.7) 217 (76.1) 231 (74.3) 205 (68.1) 0.12
Visits ratea 3.8 (6.3) 3.6 (4.6) 3.9 (5.8) 3.2 (5) 0.45
Time to first visit, months (SD) 21.1 (20.6) 25.1 (27.3) 24.8 (24.7) 26 (24.5) 0.18
Mortality for COPD (%) 55 (18.4) 52 (18) 47 (15) 30 (9.9) 0.09
Time to death, months (SD) 48.4 (34.9) 55.1 (35.2) 50.9 (34.6) 57.6 (28.3) 0.60
All-cause mortality (%) 85 (28.4) 88 (30.4) 91 (29.2) 62 (20.5) 0.02
Time to death, months (SD) 49.1 (34.7) 56.5 (34.3) 53.9 (33.9) 57.9 (30.7) 0.38
Time to first respiratory event, months (SD) 21.6 (21.7) 25.1 (28) 26.1 (26.5) 29.3 (28) 0.02
a Rates are expressed as mean number of events per patients during follow-up.
1186 J.M. Marı´n et al.the rest of the population, with a mean age of 62.1 years
and all of smokers or ex-smokers with a mean smoking
consumption of 50 pack-years, clearly fulfilling the estab-
lished criteria of COPD.
In a previous study, Hansen et al. [22] followed a cohort
of 1586 subjects and, in agreement with our results, they
found that after controlling for baseline FEV1, bronchodi-
lator reversibility was associated with better survival. In
contrast, after controlling for the best FEV1, reversibility
became non-significant and non-predictive. This study was
different from ours in that these authors included patients
with asthma and COPD and did not exclude comorbidities.
In fact, we observed that bronchodilator response was still
predictive for time to first hospitalization and time to first
respiratory event even after controlling for post-
bronchodilator FEV1, and this effect was mainly present in
those subjects in the most reversible quartile. Our results
also support those studies that have shown that post-
bronchodilator FEV1 is a significant and independent prog-
nostic factor for long-term outcomes [23,24] and differs
from the Lung Health Study analysis [24] where Mannino
et al. found a similar degree of accuracy in the prediction
of mortality for pre- and postbronchodilator FEV1. The
difference may relate to the different severity of airflow
obstruction between the populations included in these
studies. In any case, the analysis of the Lung Health Study
data did not evaluate the additive prognostic information
of reversibility in the prediction of mortality [24]. Our re-
sults concur with those observed in the ULIFT trial in which
a significantly lower mortality was observed in patients
with a BDT þ according to the same criteria used in our
study, both in the tiotropium arm (208/1357 (15.3%) for
non-responders to short-acting bronchodilators versus 152/
1520 (10%) for responders; OR: 1.63, 95%CI: 1.30e2.07) and
in the placebo arm (225/1393 (16.2%) for non-responders
versus 164/1513 (10.8%) for responders; OR: 1.58, 95%CI:
1.27e1.97) [25], supporting the concept of better long term
prognosis for reversible patients.The usefulness of acute reversibility to short-acting
bronchodilators in predicting response to pharmacological
treatment has been questioned [26]. In fact, most studies
suggest that a lack of acute response to short-acting
bronchodilators does not preclude a beneficial long-term
response to maintenance bronchodilator treatment
[25,27]. However, increased reversibility to short-acting
beta-2 agonists has been associated with a different
pattern of bronchial inflammation with an increase in eo-
sinophils and in exhaled nitric oxide (NO) [28]. As a
consequence, reversible COPD patients have demonstrated
an increased response to inhaled corticosteroids compared
with irreversible patients [14,29e33]. This differential
response to inhaled corticosteroids could justify a more
personalized approach to treatment based on a distinct
clinical phenotype [34,35].
Our study has some limitations. Restricting the analysis
to patients without comorbidities may provide a better
understanding of the role of reversibility in prognosis
without interference of comorbid diseases; however,
these results may not be extrapolated to patients with
severe comorbidities. We did not analyze the response in
lung volumes after BDT. This may be particularly impor-
tant in severe cases in which improvements in FVC may be
more frequent than improvements in FEV1 [36,37], but
only 4.7% of our cases had an FEV1 < 30% predicted. Some
characteristics that may influence outcomes were not
systematically collected at the time of the design of the
study, such as exercise capacity or degree of dyspnea. In
contrast, the study has several strengths; patients were
recruited from a pulmonary function laboratory in an
experienced teaching hospital reassuring the quality and
uniformity of spirometries and BDTs performed. Follow-up
was centralized with a dedicated group of investigators
and the aid of health registries to detect unreported
hospital visits and deaths.
In summary, the present results have shown that the
increased reversibility to short-acting beta-2 agonist is
Figure 3 (a) Probability of hospitalization for COPD in patients acco
model. (b) Probability of first respiratory event in patients according to
Table 6 Results of adjusted Cox regression analysis for
shorter time to the first hospitalization and shorter time to






Time to first hospitalization
BDT
Q1: <40 mL 1.000 e e
Q2: 40e120 mL 1.292 0.984e1.695 0.065
Q3: 120e220 mL 0.950 0.716e1.261 0.724
Q4: >220 mL 0.696 0.510e0.949 0.022
Age, older than 65 yrs 1.800 1.453e2.229 <0.001
Sex, men 0.835 0.521e1.338 0.454
BMI, Kg/m2
Normal (18.5e25) 1.000 e e
High (25e30) 0.895 0.700e1.143 0.373
Very high (>30) 0.974 0.739e1.294 0.850
Low (<18.5) 3.296 1.977e5.497 <0.001




Time to first respiratory event
BDT
Q1: <40 mL 1.000 e e
Q2: 40e120 mL 1.027 0.852e1.238 0.778
Q3: 120e220 mL 0.986 0.820e1.186 0.882
Q4: >220 mL 0.802 0.663e0.969 0.022
Age, older than 65 yrs 1.433 1.251e1.642 <0.001
Sex, men 0.755 0.572e0.995 0.046
BMI, Kg/m2
Normal (18.5e25) 1.000 e e
High (25e30) 1.001 0.851e1.179 0.988
Very high (>30) 1.109 0.925e1.330 0.265
Low (<18.5) 2.227 1.439e3.444 <0.001




BDT: Bronchodilator test; BMI: Body mass index.
Reversibility and prognosis in COPD 1187associated with better long-term outcomes in COPD pa-
tients. This association displays a doseeresponse relation-
ship, with the better outcomes observed in those in the
forth quartile of reversibility, which indicates that the
classification of subjects into positive or negative BDT ac-
cording to an arbitrary threshold should be restricted to
epidemiological studies, but may be misleading from a
clinical point of view.Funding
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